亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

恩帕吉菲 医学 安慰剂 内科学 自由水间隙 交叉研究 低钠血症 随机对照试验 肾功能 内分泌学 泌尿科 2型糖尿病 糖尿病 病理 替代医学
作者
Julie Refardt,Cornelia Imber,Rianne Nobbenhuis,Clara Odilia Sailer,Aaron Haslbauer,Sophie Monnerat,Cemile Bathelt,D. Vogt,Manfred Berres,Bettina Winzeler,Stephanie A. Bridenbaugh,Mirjam Christ‐Crain
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:34 (2): 322-332 被引量:64
标识
DOI:10.1681/asn.2022050623
摘要

Significance Statement The syndrome of inappropriate antidiuresis (SIAD) is a major cause of hypotonic hyponatremia. Despite its prevalence, treatment options are sparse, and data on their effect on hyponatremia-associated morbidity such as neurocognitive impairment are largely lacking. New treatment options are needed. The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion and could be used as a treatment for chronic SIAD. This randomized, double-blind, placebo-controlled, crossover trial with 14 participants revealed that empagliflozin is well tolerated and effective compared with placebo. In addition, treatment with empagliflozin possibly led to an improvement in neurocognitive function. The results set the stage for further studies evaluating empagliflozin as a treatment option in patients with SIAD-induced hyponatremia. Background The syndrome of inappropriate antidiuresis (SIAD) is characterized by a reduction of free water excretion with consecutive hypotonic hyponatremia and is therefore challenging to treat. The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion, likely leading to increased electrolyte free water clearance. Methods In this randomized, double-blind, placebo-controlled, crossover trial, we compared 4-week treatment with empagliflozin 25 mg/d to placebo in outpatients with chronic SIAD-induced hyponatremia. At baseline and after both treatment cycles, patients underwent different assessments including neurocognitive testing (Montreal Cognitive Assessment [MoCA]). The primary end point was the difference in serum sodium levels between treatments. Results Fourteen patients, 50% female, with a median age of 72 years (interquartile range [IQR], 65–77), completed the trial. Median serum sodium level at baseline was 131 mmol/L (IQR, 130–132). After treatment with empagliflozin, median serum sodium level rose to 134 mmol/L (IQR, 132–136), whereas no increase was seen with placebo (130 mmol/L; IQR, 128–132), corresponding to a serum sodium increase of 4.1 mmol/L (95% confidence interval [CI], 1.7 to 6.5; P =0.004). Exploratory analyses showed that treatment with empagliflozin led to improved neurocognitive function with an increase of 1.16 (95% CI, 0.05 to 2.26) in the MoCA score. Treatment was well tolerated; no serious adverse events were reported. Conclusion The SGLT2 inhibitor empagliflozin is a promising new treatment option for chronic SIAD-induced hyponatremia, possibly improving neurocognitive function. Larger studies are needed to confirm the observed treatment effects. Clinical Trial registration number: ClinicalTrials.gov NCT03202667.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被amiee采纳,获得10
刚刚
1秒前
痞老板死磕蟹黄堡完成签到 ,获得积分10
6秒前
7秒前
wuyp发布了新的文献求助10
8秒前
深情安青的应助被晚风采纳,获得10
12秒前
fantasy的应助被科研通管家采纳,获得10
14秒前
乐乐的应助被科研通管家采纳,获得10
14秒前
CAOHOU的应助被科研通管家采纳,获得10
14秒前
Yanyu发布了新的文献求助40
14秒前
852的应助被wuyp采纳,获得10
14秒前
Karma完成签到,获得积分10
20秒前
21秒前
25秒前
杉寒完成签到,获得积分10
26秒前
晚风发布了新的文献求助10
26秒前
32秒前
华仔的应助被晚风采纳,获得10
41秒前
胡德完成签到 ,获得积分10
42秒前
wei完成签到 ,获得积分10
44秒前
lin完成签到,获得积分10
46秒前
勤奋笙的应助被Celia采纳,获得100
52秒前
53秒前
Yanyu发布了新的文献求助20
54秒前
HCl完成签到,获得积分10
54秒前
54秒前
西扬完成签到 ,获得积分10
56秒前
1分钟前
晚风发布了新的文献求助10
1分钟前
科研通AI6.4的应助被萧雨墨采纳,获得10
1分钟前
二橦完成签到,获得积分10
1分钟前
1分钟前
靓丽的小懒虫完成签到,获得积分10
1分钟前
1分钟前
1分钟前
leo发布了新的文献求助10
1分钟前
星辰大海的应助被sunzp采纳,获得10
1分钟前
caca完成签到,获得积分0
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190078
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21851985
捐赠科研通 7788239
什么是DOI,文献DOI怎么找? 3436236
关于科研通互助平台的介绍 2559951
邀请新用户注册赠送积分活动 2482818